6533b7dcfe1ef96bd12720ca

RESEARCH PRODUCT

Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth

Guido CavalettiTina ColomboNorberto OggioniGiulia De MicheleVirginia Rodriguez-menendezAlessandra SfacteriaSara MartoneMaurizio D'incalciGiuseppe PiedemonteGiovanni GrassoGiuseppe LauriaAnnalisa CantaAlessandra GilardiniRoberto BianchiPatrizia BeccagliaPietro Ghezzi

subject

medicine.medical_specialtyCancer ResearchPeripheral neuropathyNeural ConductionNeurophysiologyAntineoplastic AgentsHindlimbHematocritNeuroprotectionAntineoplastic AgentInternal medicinemedicinePathologyAnimalsRats WistarErythropoietinCisplatincisplatin; Erythropoietin; peripheral neuropathy; tumor growthmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnimalNeurotoxicityPeripheral Nervous System DiseasesMammary Neoplasms ExperimentalTumour growthHematologymedicine.diseaseRatsHindlimbDose–response relationshipPeripheral neuropathyEndocrinologyOncologyHematocritErythropoietinRatFemalePeripheral Nervous System DiseaseCisplatinbusinessCell Divisionmedicine.drug

description

This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 microg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 microg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 microg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in rats bearing mammary carcinoma EPO treatment (50 microg/kg ip) given concurrently with CDDP (1.0 and 1.5 mg/kg twice a week for four weeks) was neuroprotective without influencing the effectiveness of the treatment or tumour growth. EPO thus appears to be an effective neuroprotectant that does not interfere with tumour treatment.

10.1016/j.ejca.2006.09.028http://hdl.handle.net/10281/20348